Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial
about
Antioxidant vitamin and mineral supplements for preventing age-related macular degenerationAntioxidant vitamin and mineral supplements for slowing the progression of age-related macular degenerationA longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal functionGeographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospectsNitroxide pharmaceutical development for age-related degeneration and diseaseCurrent therapeutic developments in atrophic age-related macular degenerationAge-Related Macular Degeneration: Advances in Management and DiagnosisNrf2 Is an Attractive Therapeutic Target for Retinal DiseasesNano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degenerationUpdate on current and future novel therapies for dry age-related macular degeneration.Dry age-related macular degeneration: A currently unmet clinical need.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry.Clinical characteristics and current treatment of age-related macular degeneration.670-nm light treatment reduces complement propagation following retinal degeneration.Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.Apigenin Attenuates Oxidative Injury in ARPE-19 Cells thorough Activation of Nrf2 Pathway.Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina.Emerging therapeutic approaches in the management of retinal angiogenesis and edema.Therapeutic targeting of the complement system in age-related macular degeneration: a review.Consequences of oxidative stress in age-related macular degeneration.Bowman lecture on the role of inflammation in degenerative disease of the eye.Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.Dry Age-Related Macular Degeneration Pharmacology.CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases.Recent developments in age-related macular degeneration: a review.Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.Oxidative stress and reactive oxygen species: a review of their role in ocular disease.Lipid radicals cause light-induced retinal degeneration.
P2860
Q24202679-38412226-5BE7-480E-B035-037B91C96300Q24202824-28A97691-EC6B-4811-89CC-9FDCCCF225FBQ24628705-55CB743F-178D-49BB-B4E8-389CC606ED26Q26774188-FBAA552F-14A2-418E-BDCB-3E80812C2E4BQ26776523-43201E1A-B36C-4C33-92F2-B336F655688FQ26778247-F9B57B41-6D9C-4483-AB26-2262FCD6000CQ26799617-4A4F4866-5B9A-41D5-A432-77C0C443EF8EQ28077181-ABD247FA-F97D-4B73-9A09-808DC9C58D42Q30565636-44985A79-A719-4034-B6F8-B7850F48587BQ34366170-4DF26637-0CB7-4894-A406-EDFD5E3BC298Q34378033-7CE45303-46F6-4F9B-AC1C-CA069B4F58DFQ34530196-9E8AE210-D23D-49AD-B192-1F0BA1A9379CQ34645582-E513B683-6304-4447-A560-BEFE6F235583Q34930298-EFCFD6C4-F894-46FD-B115-1B6F1BB28DFCQ36454668-128B417F-F0FE-4200-8FC2-95D2F7968E2CQ36801990-08B35C1C-7703-41F0-A881-EF7CFB4045C5Q37253965-FE021B8E-82CE-410E-B95E-4AB858D6778FQ37645117-E291E913-56F0-4C62-A5AE-C61B0E2AEC18Q37822290-2E3E8332-EEE3-4240-B14A-1A21C3307C0AQ37981256-1FB38CDA-C619-4FF2-85A5-EA7E7DE5DBAEQ38003229-3214CA98-A2FF-4173-8378-7AC3E414F0ACQ38071535-92290249-3BCE-4206-8B93-51A00E7B7B23Q38653249-A71016F5-ABBF-49AB-AC93-16D384B86D76Q38653252-BE2CE441-41A3-4824-834C-DDAB8A3C61EBQ38789140-A61148BE-C192-4A2A-AC2B-025AA5523DFEQ38818680-CFD20F44-77D6-4C78-ABEE-425A6ACBFADFQ39039446-C12D99E2-E7F3-44BA-917A-A0783EE648FEQ41532061-AFB35149-76E3-4829-BAB1-A27D67DBCDA2Q45870879-B630FB47-0892-4F07-BC70-A49E1F8F18BDQ46248374-F31AFDE8-B76B-42D6-A488-14D15E2634DBQ49994873-75C29CC1-0006-4679-9465-1866A906A441
P2860
Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Treatment of geographic atroph ...... s of a phase II clinical trial
@ast
Treatment of geographic atroph ...... s of a phase II clinical trial
@en
Treatment of geographic atroph ...... s of a phase II clinical trial
@nl
type
label
Treatment of geographic atroph ...... s of a phase II clinical trial
@ast
Treatment of geographic atroph ...... s of a phase II clinical trial
@en
Treatment of geographic atroph ...... s of a phase II clinical trial
@nl
prefLabel
Treatment of geographic atroph ...... s of a phase II clinical trial
@ast
Treatment of geographic atroph ...... s of a phase II clinical trial
@en
Treatment of geographic atroph ...... s of a phase II clinical trial
@nl
P2093
P2860
P356
P1476
Treatment of geographic atroph ...... s of a phase II clinical trial
@en
P2093
Catherine B Meyerle
Denise Cunningham
Frederick L Ferris
Keri Hammel
Molly Harrington
Srinivas R Sadda
Wai T Wong
Waynekid Kam
P2860
P304
P356
10.1167/IOVS.10-5637
P407
P577
2010-06-23T00:00:00Z